Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...
Read Full NewsA groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.
Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!
Here's some of what is coming soon to NeurologyLive® this week.
FDA Clears LEADOPTIK's LIA System for Higher-Accuracy Lung Biopsy
1.
Dietary Intervention Shows Promise in Blood Cancers
2.
Using MRD Status to Deescalate Multiple Myeloma Therapy
3.
Minimally invasive prostate cancer treatment shows success in first patient
4.
automated, precise reporting for clonality testing using NGS.
5.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
1.
Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation
2.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
3.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
4.
Obesity is a major risk factor for cancer
5.
Integrative Cancer Care: Nutrition, Social Work, Care Coordination, and Genetic Counseling
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge